Explore Clinical Trials Results
Total Trials: 109
Study ID:
101-04
Study Title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-101 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge
Study ID:
101-07
Study Title:
A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination with Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Study ID:
101-08
Study Title:
A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 alone and in Combination With Rituximab in Elderly Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study ID:
101-09
Study Title:
A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
Study ID:
101-10
Study Title:
Single-agent CAL-101 for Previously treated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events
Study ID:
101-11
Study Title:
A Phase 2 Study to Assess the Efficacy and Safety of GS-1101 (CAL-101) in Patients with Relapsed or Refractory Hodgkin Lymphoma
Study ID:
101-99
Study Title:
An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients With Hematologic Malignancies
Study ID:
GS-US-292-0102
Study Title:
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Study ID:
GS-US-292-0104
Study Title:
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Study ID:
GS-US-292-0111
Study Title:
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Study ID:
GS-US-292-0112
Study Title:
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients with Mild to Moderate Renal Impairment
Study ID:
GS-US-292-0117
Study Title:
A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Study ID:
GS-US-292-0119
Study Title:
A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Study ID:
GS-US-292-1249
Study Title:
A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults
Study ID:
GS-US-292-1515
Study Title:
A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents
Study ID:
GS-US-292-1823
Study Title:
A Phase 3b Randomized Open-Label Study to Evaluate the Benefit of Switching from Regimens Consisting of abacavir/lamivudine (ABC/3TC) plus a third agent to the Elvitegravir /Cobicistat /Emtricitabine /Tenofovir alafenamide (E/C/F/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adult Patients
Study ID:
GS-US-292-1824
Study Title:
A Phase 3b Open-Label Pilot Study to Evaluate Switching to
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF)
Fixed Dose Combination in Virologically-Suppressed HIV-1 Infected
Adult Subjects Harboring the Archived Isolated NRTI Resistance
Mutation M184V/M184I
Study ID:
GS-US-292-1825
Study Title:
A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability,
Pharmacokinetics and Efficacy of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose
Combination in HIV-1 Infected Adults on Chronic Hemodialysis
Study ID:
GS-US-292-1826
Study Title:
A Phase 3b, Randomized, Open-Label Study to Evaluate Switching from a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years
Study ID:
GS-US-311-1089
Study Title:
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV 1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF
Study ID:
GS-US-311-1717
Study Title:
A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing ABC/3TC
Study ID:
GS-US-312-0115
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Study ID:
GS-US-312-0116
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Study ID:
GS-US-312-0117
Study Title:
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia
A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Study ID:
GS-US-312-0118
Study Title:
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Study ID:
GS-US-312-0119
Study Title:
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Study ID:
GS-US-312-0123
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia
Study ID:
GS-US-312-0133
Study Title:
A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion
Study ID:
GS-US-312-1325
Study Title:
An Expanded Access Protocol for Idelalisib (GS 1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia who have limited treatment options
Study ID:
GS-US-312-1579
Study Title:
A Phase 1b/2 Study of Idelalisib in Combination with BI 836826 in Subjects with Chronic Lymphocytic Leukemia
Study ID:
GS-US-313-0124
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evalutating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Study ID:
GS-US-313-0125
Study Title:
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Study ID:
GS-US-313-1380
Study Title:
A Phase 1 b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in
Japanese Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or
Chronic Lymphocytic Leukemia
Study ID:
GS-US-313-1414
Study Title:
A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination with Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Study ID:
GS-US-313-2120
Study Title:
An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kδ Inhibitor, GS-9820
Study ID:
GS-US-313-4100
Study Title:
Immune Response to the Influenza Vaccine in Subjects Treated with Idelalisib
Study ID:
GS-US-320-0101
Study Title:
A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics and Anti-HBV Activity of GS-7340 in Treatment-Naïve Adults with Chronic Hepatitis B (CHB) Infection
Study ID:
GS-US-320-1196
Study Title:
A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability of a Pediatric Oral Granule Formulation of Tenofovir Alafenamide in Healthy Adults
Study ID:
GS-US-320-1615
Study Title:
A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects with Normal Hepatic Function and Subjects with Severe Hepatic Impairment
Study ID:
GS-US-337-0102
Study Title:
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0108
Study Title:
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 or 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0109
Study Title:
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Experienced Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0113
Study Title:
A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0115
Study Title:
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Study ID:
GS-US-337-0118
Study Title:
A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed Dose Combination ± Ribavirin in Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0121
Study Title:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for 24 Weeks Without Ribavirin in Treatment-Experienced Cirrhotic Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0122
Study Title:
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection
Study ID:
GS-US-337-0123
Study Title:
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant
Study ID:
GS-US-337-0124
Study Title:
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant
Study ID:
GS-US-337-0125
Study Title:
An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Nosocomial Genotype 1 HCV Infection
Study ID:
GS-US-337-0131
Study Title:
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-0133
Study Title:
A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination with Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naïve or Treatment-Experienced Cirrhotic Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-337-1115
Study Title:
A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric
Granules Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects
Study ID:
GS-US-337-1116
Study Title:
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection
Study ID:
GS-US-337-1118
Study Title:
An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study
Study ID:
GS-US-337-1119
Study Title:
A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genotype 4 or 5 HCV Infection
Study ID:
GS-US-337-1405
Study Title:
An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination
for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects with Sickle Cell Disesase
Study ID:
GS-US-337-1406
Study Title:
A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chronic HCV Infection
Study ID:
GS-US-337-1428
Study Title:
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and
Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered
in Patients Infected with Chronic HCV for Use in the Peri-Operative Liver
Transplantation Setting
Study ID:
GS-US-337-1445
Study Title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of –Ledipasvir-Sofosbuvir Fixed Dose
Combination on Neurogognition and Cerebral Metabolism in Patients with Chronic Genotype 1 Hepatitis C
Study ID:
GS-US-337-1463
Study Title:
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults with Chronic HCV Infection
Study ID:
GS-US-337-1468
Study Title:
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens
for the Treatment of Chronic HCV Infection
Study ID:
GS-US-337-1512
Study Title:
A Phase 2, Randomized, Open Label Study of Ledipasvir/Sofosbuvir
Fixed Dose Combination and Vedroprevir with or without Ribavirin in
Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection and
Cirrhosis
Study ID:
GS-US-337-1612
Study Title:
A Phase 2, Open-Label etrial evaluating ledipasvir and sofosbuvir fixed dose combination for 6 weeks in the treatment of acute hepatitis C genotype 1 and 4 infection in patients with
HIV-1 co-infection
Study ID:
GS-US-337-1643
Study Title:
A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and
Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, with or
without Ribavirin, in Egyptian Adults with Chronic Genotype 4 HCV
Infection
Study ID:
GS-US-337-1655
Study Title:
A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir
Fixed-Dose Combination for 12 Weeks in Subjects with Chronic
Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus
(HBV) Coinfection
Study ID:
GS-US-337-1701
Study Title:
A Phase 2 Open-Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection
Study ID:
GS-US-337-1746
Study Title:
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Study ID:
GS-US-337-1903
Study Title:
A Phase 3b, Multicenter, Randomized, Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects Infected with Chronic HCV Genotype 2
Study ID:
GS-US-337-1904
Study Title:
A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/sofosbuvir Fixed Dose Combination in Treatment of Hepatitis C Virus (HCV) infection in Adolescents Undergoing Cancer Chemotherapy
Study ID:
GS-US-337-2091
Study Title:
A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Granule Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects
Study ID:
GS-US-337-4063
Study Title:
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease
Study ID:
GS-US-342-0102
Study Title:
A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection
Study ID:
GS-US-342-0109
Study Title:
A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects with Chronic HCV Infection
Study ID:
GS-US-342-1137
Study Title:
A Phase 3, Multicenter, Open-Label Study to Investigate the
Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose
Combination in Subjects with Chronic HCV Infection and
Child-Pugh Class B Cirrhosis
Study ID:
GS-US-342-1138
Study Title:
Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV Infection
Study ID:
GS-US-342-1139
Study Title:
Phase 3, Multicenter, Randomized, Open-Label Study to Compare the
Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with
Chronic Genotype 2 HCV Infection
Study ID:
GS-US-342-1140
Study Title:
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection
Study ID:
GS-US-342-1142
Study Title:
A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of SOF/VEL in Healthy Adult Subjects
Study ID:
GS-US-342-1202
Study Title:
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of
Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects
with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency
Virus (HIV)-1 Coinfection
Study ID:
GS-US-342-1446
Study Title:
Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection
Study ID:
GS-US-342-1518
Study Title:
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and
Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in
Subjects with Chronic HCV
Study ID:
GS-US-342-1521
Study Title:
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection
Study ID:
GS-US-342-1522
Study Title:
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection
Study ID:
GS-US-342-1553
Study Title:
An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study
Study ID:
GS-US-342-2083
Study Title:
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected with Chronic HCV in the Peri-Operative Liver Transplantation Setting
Study ID:
GS-US-342-2097
Study Title:
A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
Study ID:
GS-US-342-2104
Study Title:
A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir in Subjects with Chronic HCV Infection who have Received a Liver Transplant
Study ID:
GS-US-342-3921
Study Title:
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects with Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Study ID:
GS-US-342-4019
Study Title:
A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and Decompensated Cirrhosis
Study ID:
GS-US-342-4022
Study Title:
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir and Ribavirin in Subjects with Chronic HCV Infection and Child-Pugh Turcotte C Cirrhosis
Study ID:
GS-US-342-4062
Study Title:
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease
Study ID:
GS-US-366-1160
Study Title:
A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects
Study ID:
GS-US-366-1216
Study Title:
A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Study ID:
GS-US-366-1992
Study Title:
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs study (Co-infection treatment with Single Tablet Antiviral Regimens)
Study ID:
GS-US-367-1168
Study Title:
A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection
Study ID:
GS-US-367-1169
Study Title:
A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection
Study ID:
GS-US-367-1170
Study Title:
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection who Have Not Received an NS5A Inhibitor
Study ID:
GS-US-367-1171
Study Title:
A Phase 3, Global, Multicenter, Randomized, Double-Blind,
Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection
Study ID:
GS-US-367-1172
Study Title:
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naive Subjects with Chronic HCV Infection
Study ID:
GS-US-367-1173
Study Title:
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis
Study ID:
GS-US-367-1871
Study Title:
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS 5816/GS-9857 Fixed-Dose Combination with or without Ribavirin in Subjects with Chronic Genotype 1 HCV Infection Previously Treated with a Direct Acting Antiviral Regimen
Study ID:
GS-US-367-1909
Study Title:
A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
Study ID:
GS-US-367-4181
Study Title:
An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Study ID:
GS-US-380-1844
Study Title:
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV 1 Infected Subjects who are Virologically Suppressed
Study ID:
GS-US-380-1961
Study Title:
A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) from Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women
Study ID:
GS-US-418-3898
Study Title:
Combined Phase 2b/3, Double-Blind, Randomized,
Placebo-Controlled Studies Evaluating the Efficacy and Safety
of Filgotinib in the Induction and Maintenance of Remission in
Subjects with Moderately to Severely Active Ulcerative Colitis
Study ID:
GS-US-540-5773
Study Title:
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19
Study ID:
GS-US-540-5774
Study Title:
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Paiiicipants with Moderate COVID-19 Compared to Standard of Cai·e Treatment
Some of the content on this page is not intended for users outside the US.